ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.

PRNewsWire • Jun 24, 2026

Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, both members of the Taiho group, today announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) for the treatment of non-Hodgk.

Business Wire • Jun 23, 2026

Agree Realty: This Dividend Compounder Looks Attractive Again

Agree Realty is a high-quality net lease REIT with strong exposure to investment-grade, necessity-based retail tenants and a robust development platform. ADC delivered 7.9% YoY AFFO per share growth in Q1 2026, with a 104% rent recapture rate and active capital recycling supporting bottom-line expansion. I maintain a "buy" rating on ADC, citing its 4.3% yield, conservative 3.2x net debt/EBITDA, and well-covered 70% payout ratio.

Seeking Alpha • Jun 18, 2026

2 Monthly Dividend REITs, Only 1 Is A Buy Today

Monthly dividends do not always mean equal quality. One popular REIT may be riskier than it looks. The safer pick could offer better risk-adjusted upside.

Seeking Alpha • Jun 17, 2026

June's 5 Dividend Growth Stocks With Yields Up To 6.47%

Every month, we screen for dividend growth stocks, highlighting value and income opportunities with high safety, growth, and consistency quant grades. There are several blue-chip names that have populated near the top of the list as potential turnaround plays. We also have a small retail-focused REIT being brought up this month that could be an interesting potential acquisition target for larger players.

Seeking Alpha • Jun 18, 2026

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

PRNewsWire • Jun 17, 2026

Why Your REIT Strategy Is Likely Failing You, And What To Do Instead

Five common REIT mistakes can quietly destroy returns. Today's winners often look unattractive at first glance. Avoiding these traps helped us beat the sector.

Seeking Alpha • Jun 16, 2026

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer. HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally.

PRNewsWire • Jun 15, 2026

3 Elite Dividend Machines That Could Pay Your Bills For Decades

Dependable dividend growth machines are more valuable than ever in a higher-for-longer inflationary environment. I detail three of the very best that are trading at attractive valuations and combine outsized current yields with inflation-beating dividend growth profiles for the long-term. I also share the risk profiles for each of them.

Seeking Alpha • Jun 10, 2026

Agree Realty And Global Net Lease: One Yields 4%, One Yields 8%. The Balance Sheet Sets The Spread.

Agree Realty (NYSE:ADC) and Global Net Lease (NYSE:GNL) own the same kind of asset — single-tenant properties leased on long-term, triple-net terms — and report it very differently.

Benzinga • Jun 9, 2026